Heart failure with preserved ejection (HFpEF) is a condition underlined by impaired left ventricular (LV) diastolic function in the presence of normal contractile function, occurring due to the complex interplay between cardiometabolic comorbidities, inflammatory changes, volume overload and increased stiffness resulting in abnormal LV remodelling (1). HFpEF patients who are obese have been shown to demonstrate worse clinical and haemodynamic features compared to patients without obesity (2). Therefore, this patient population may respond favourably to weight loss measures. Glucagon-like peptide 1 (GLP-1) receptor agonists are an established treatment for type 2 diabetes mellitus and obesity, and have been shown to achieve effective weight loss and reduce major adverse cardiovascular events in those with concomitant cardiovascular or renal disease (3). Although a high proportion of patients with HFpEF are also obese, there is a paucity of obesity-targeting therapies in this particular population.
Authors Heartbeat Sub-Editor: Sandeep Singh Dr Sandeep Singh is a Cardiology Clinical Fellow at Nottingham University Hospitals NHS Trust. After graduating from India, he completed
Authors Heartbeat Sub-Editor: Khin Kay Kay Kyaw I am currently working as cardiology specialist registrar ST6 at southwest peninsula region while also working as an
Authors Heartbeat Sub-Editor: Anindya Mukherjee Dr. Anindya Mukherjee is a ST5 trainee registrar in Cardiology at Mid Yorkshire Teaching NHS Trust, UK, with extensive experience
Authors Sub-editor: Sameer Zaman Heartbeat Sub-Editor: Aleena Haider Aleena is an academic cardiology trainee at Imperial College London with a strong commitment to all aspects
Authors Sub-editor: Sameer Zaman Heartbeat Sub-Editor: Padraig O Drisceoil Dr Pádraig Ó Drisceoil is a Cardiology Speciality Trainee from the Wessex Deanery, who is currently an
